Renal cell carcinoma: A priority malignancy for development and study of novel therapies

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1193-1194

  Motzer, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; NEPHRECTOMY; NOTE; RANDOMIZED CONTROLLED TRIAL;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; RANDOMIZED CONTROLLED TRIALS;

EID: 0037837712     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.072     Document Type: Editorial

References (17)

1. Messing EM, Manola J, Wilding G, et al: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 21:1214-1222, 2003
2. Porzsolt F: Adjuvant therapy of renal cell cancer with interferon alfa-2a. Proc Am Soc Clin Oncol 11:202, 1992 (abstr 622)
3. Pizzocaro G, Piva L, Costa A, et al: Adjuvant interferon to radical nephrectomy in Robson's stage II and III renal cell cancer: A multicenter randomized study with some biological evaluations. Proc Am Soc Clin Oncol 16:318a, 1997 (abstr 1132)
4. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
5. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 163:408-417, 2000
6. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6:S55-S57, 2000 (suppl)
7. Pyrhonen S, Salminen E, Ruutu M, et al: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859-2867, 1999
8. Medical Research Council and Collaborators: Interferon-alfa and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 353:14-17, 1999
9. Motzer R, Bacik J, Murphy BA, et al: Interferon alfa as a comparative treatment for clinical trials of new therapies against renal cell carcinoma. J Clin Oncol 20:289-296, 2002
10. Motzer RJ, Mazumdar M, Bacik J, et al: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928-1935, 2000
11. Jones P, Vogelzang N: Priorities of the kidney/bladder cancer progress review group. Bethesda, MD, National Cancer Institute, 2002; http://prg.nci.nih.gov/kidney/finalreport.html
12. Schmidt L, Junker K, Nakaigawa N, et al: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350, 1999
13. Vogelzang NJ, Priest ER, Borden L: Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: A case with 5-year followup. J Urol 148:1247-1248, 1992
14. Gleave ME, Elhilali M, Fradet Y, et al: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338:1265-1271, 1998
15. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokineactivated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-632, 1993
16. Abrams JS, Rayner AA, Wiernik PH, et al: High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst 82:1202-1206, 1990
17. Stadler WM, Kuzel T, Dumas M, et al: A multi-center phase II trial of interleukin-2, interferon-alpha, and 13 cis-retinoic acid in patients with metastatic renal cell carcinoma. J Clin Oncol 16:1820-1825, 1998